title: Epidemiological trends for hospital admissions for acute rotavirus gastroenteritis in Belgium following the introduction of routine rotavirus vaccination and the subsequent switch from lyophilized to liquid formulation of Rotarix™.
abstract: This study describes epidemiological trends for acute rotavirus gastroenteritis (RVGE) in Belgium in children aged ⩽5 years during the period June 2007 to May 2014 after the introduction of routine rotavirus (RV) vaccination. This period encompassed the switch from lyophilized to the liquid formulation of Rotarix™ (GlaxoSmithKline, Belgium) in August 2011. Uptake of RV vaccine remained consistently high throughout the study period with Rotarix the brand most often used. RV was present in 9% (1139/12 511) of hospitalized cases with acute gastroenteritis included in the study. Epidemiological trends for hospital admissions for RVGE remained consistent throughout the study period, with no evidence of any change associated with the switch from lyophilized to liquid formulation of Rotarix. This suggests both formulations perform similarly, with the liquid formulation not inferior regarding ability to reduce hospital admissions for acute RVGE in children aged ⩽5 years. A strong seasonal effect was observed with most RVGE occurring in the winter months but with some variability in intensity, with highest incidence found in those aged 6-24 months. The main observation was the decreased number of hospital admissions for RVGE in Belgium that occurred during winter 2013/2014.
authors.affiliation: Jessa Hospital, Pediatrics,Hasselt,Belgium.
authors.forename: M
authors.initials: M
authors.lastname: Raes
authors.affiliation: Realidad, Health Economics,Grimbergen,Belgium.
authors.forename: D
authors.initials: D
authors.lastname: Strens
authors.affiliation: Deloitte, HEOR,Diegem,Belgium.
authors.forename: J
authors.initials: J
authors.lastname: Kleintjens
authors.affiliation: Deloitte, HEOR,Diegem,Belgium.
authors.forename: E
authors.initials: E
authors.lastname: Biundo
authors.affiliation: Clinical Pharmacology and Pharmacotherapy,KU Leuven,Belgium.
authors.forename: T
authors.initials: T
authors.lastname: Morel
authors.affiliation: GSK Vaccines,Wavre,Belgium.
authors.forename: A
authors.initials: A
authors.lastname: Vyse
mesh_terms: D000208:Acute Disease; D001530:Belgium / Q000453:epidemiology; D002675:Child, Preschool; D005260:Female; D006760:Hospitalization / Q000706:statistics & numerical data / Q000639:trends; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D012401:Rotavirus / Q000276:immunology*; D012400:Rotavirus Infections / Q000453:epidemiology* / Q000517:prevention & control / Q000821:virology; D022243:Rotavirus Vaccines / Q000627:therapeutic use*; D014611:Vaccination / Q000706:statistics & numerical data; D014613:Vaccines, Attenuated / Q000627:therapeutic use
chemical_list: C492457:RIX4414 vaccine; C492535:RotaTeq; D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated
keywords: Acute; Belgium; Rotarix™ vaccination; epidemiological; gastroenteritis; rotavirus; trend